MetLife (MET) U.S. Business president awarded 127 shares via deferred plan

Rhea-AI Filing Summary

MetLife Inc. reported that President, U.S. Business Ramy Tadros acquired 127 shares of common stock on June 9, 2026. The shares were credited at an imputed price of $85.57 per share through reinvested dividends in the MetLife Leadership Deferred Compensation Plan, increasing his direct holdings to 216,946 shares. This reflects routine compensation-related accrual rather than an open-market purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider TADROS RAMY

Role President, U.S. Business

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	127	$85.57	$11K

Holdings After Transaction: Common Stock — 216,946 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares awarded: 127 shares Imputed price per share: $85.57 per share Total shares after transaction: 216,946 shares

3 metrics

Shares awarded 127 shares Common Stock grant on June 9, 2026

Imputed price per share $85.57 per share Valuation used for dividend reinvestment

Total shares after transaction 216,946 shares Direct holdings following award

Key Terms

MetLife Leadership Deferred Compensation Plan, deferred shares, imputed reinvestment of dividends

3 terms

MetLife Leadership Deferred Compensation Plan financial

"Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Leadership Deferred Compensation Plan."

deferred shares financial

"Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the reporting person has deferred."

Deferred shares are a class of stock whose economic benefits or certain shareholder rights are delayed or paid later than ordinary shares—for example, dividends may be paid only after other shareholders receive theirs, or voting or redemption rights may be postponed. For investors, that timing difference matters because deferred shares typically offer lower near-term income and different risk, affecting expected returns, priority in payouts, and the share’s market value; think of them like a delayed paycheck compared with a regular salary.

imputed reinvestment of dividends financial

"Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Leadership Deferred Compensation Plan."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TADROS RAMY

(Last) (First) (Middle)

METLIFE, INC.

200 PARK AVENUE

(Street)

NEW YORK NEW YORK 10166

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, U.S. Business

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/09/2026		A(1)		127	A	$85.57	216,946	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Leadership Deferred Compensation Plan. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the reporting person has deferred.

Remarks:

The reporting person's disclosure rounds deferred shares to the nearest whole number.

	/s/ Morgan Keehner-Jones Mayes, Attorney-in-fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did MetLife (MET) report for Ramy Tadros?

MetLife reported that Ramy Tadros received 127 shares of common stock as a compensation-related award. The shares were credited via dividend reinvestment in a deferred compensation plan, rather than bought on the open market, modestly increasing his direct ownership stake.

Was the Ramy Tadros Form 4 transaction in MetLife (MET) a stock purchase?

The transaction was not an open-market stock purchase. Tadros received 127 shares through imputed reinvestment of dividends in the MetLife Leadership Deferred Compensation Plan, classified as a grant or award acquisition rather than a discretionary buy on a stock exchange.

How many MetLife (MET) shares does Ramy Tadros hold after this Form 4 filing?

After the award of 127 shares, Tadros directly holds 216,946 shares of MetLife common stock. The filing shows this updated total ownership figure, indicating the new grant is a relatively small addition to his existing equity position in the company.

What is the MetLife Leadership Deferred Compensation Plan mentioned in the Form 4?

The MetLife Leadership Deferred Compensation Plan allows certain compensation to be deferred and linked to MetLife common stock. In this filing, dividends on deferred shares were imputed and reinvested, resulting in 127 additional deferred shares that have become payable but whose receipt Tadros has deferred.

At what price were the new MetLife (MET) shares credited to Ramy Tadros?

The 127 additional shares were credited at an imputed price of $85.57 per share. This price is used for calculating the number of shares received through dividend reinvestment under the deferred compensation plan, not as an open-market trade price.